RETINALAMIN
Retinalamin is a complex of polypeptides isolated from the retina of cattle, studied as a bioregulatory agent for retinal neuroprotection, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, and glaucoma in Russian clinical practice.
Retinalamin is a complex bioregulatory peptide preparation isolated from the retina of cattle and pigs, consisting of a mixture of polypeptides with molecular weights up to 10 kDa. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson and Professor Svetlana Trofimova, Retinalamin represents the tissue-specific bioregulator approach applied to ophthalmology.
Mechanism of Action
Retinalamin operates through the tissue-specific bioregulatory framework described by Khavinson (2005), in which peptides derived from a given tissue exert preferential regulatory effects on the cells and gene expression patterns of that same tissue type.
Retinal Cell Functional Activation: The polypeptide complex enhances the functional activity of retinal cells through tissue-specific peptide signaling. Studies by Trofimova et al. (2004) demonstrated that Retinalamin stimulates protein synthesis in retinal pigment epithelium (RPE) cells, promoting cellular repair and maintenance processes essential for photoreceptor support.
Antioxidant Protection: Retinal tissue is highly susceptible to oxidative damage due to constant light exposure and high metabolic oxygen demand. Retinalamin has been shown to enhance antioxidant defense mechanisms in retinal cells, reducing lipid peroxidation and protecting photoreceptors from free radical damage (Khavinson & Trofimova, 2004).
Anti-Inflammatory Activity: The peptide complex modulates inflammatory signaling in the retinal microenvironment, reducing cytokine-mediated inflammation that contributes to the progression of AMD, diabetic retinopathy, and other degenerative conditions (Maksimov et al., 2009).
Retinal Pigment Epithelium Stabilization: RPE dysfunction is a central feature of AMD pathogenesis. Retinalamin stabilizes RPE function by modulating gene expression patterns involved in phagocytosis of photoreceptor outer segments, melanin synthesis, and growth factor secretion (Trofimova et al., 2004).
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Diabetic Retinopathy
Retinalamin has been studied as an adjunct therapy in non-proliferative diabetic retinopathy. Khavinson et al. (2005) described improvements in retinal electrophysiology and visual field parameters in diabetic patients receiving Retinalamin courses. The neuroprotective and anti-inflammatory properties of the peptide complex are proposed to address the microvascular and neuronal damage characteristic of diabetic eye disease.
Retinitis Pigmentosa
Related research by Khavinson et al. (2002) demonstrated that the tetrapeptide Epithalon improved retinal outcomes in 90% of rats with retinitis pigmentosa, preserving normal eye structure and bioelectric function. Retinalamin, as a broader retinal polypeptide complex, has been used clinically in retinitis pigmentosa patients with reported improvements in ERG parameters and visual field preservation, complementing the Epithalon findings.
Photoreceptor Neuroprotection
Experimental studies have demonstrated that retinal peptide bioregulators protect photoreceptor cells against light-induced damage and oxidative stress. Khavinson (2005) characterized the broader mechanisms by which tissue-specific peptides modulate gene expression in target tissues, with retinal peptides showing preferential activity on photoreceptor and RPE cell gene expression profiles.
Glaucoma
Open-angle glaucoma involves progressive retinal ganglion cell loss. Retinalamin has been investigated as a neuroprotective agent in glaucoma management, with clinical reports suggesting improved ganglion cell function as measured by pattern ERG and visual evoked potentials following treatment courses (Egorov et al., 2004).
Age-Related Macular Degeneration
Clinical studies in Russian ophthalmology settings have evaluated Retinalamin in patients with dry (atrophic) AMD. Maksimov et al. (2009) reported improvements in visual acuity, electroretinogram (ERG) parameters, and retinal sensitivity following courses of parabulbar Retinalamin injections in elderly patients with AMD. The treatment was associated with stabilization of visual function and slowed disease progression over follow-up periods of 6-12 months.
Safety Profile
Retinalamin has been used clinically in Russia for over two decades with a favorable safety profile. Reported adverse effects are limited to mild local reactions at the injection site (parabulbar route), including transient pain, swelling, and redness. No systemic adverse effects have been reported at the recommended dose of 5 mg daily for 10 days. The preparation is contraindicated in patients with known hypersensitivity to animal-derived proteins. As a mixture of bovine/porcine retinal peptides, theoretical risks include allergic reactions to animal proteins, though such events have not been prominently reported in the published literature. No controlled long-term safety studies meeting international regulatory standards have been published.
Pharmacokinetic Profile
- Half-life
- Short (peptide mixture, rapidly degraded)
- Metabolism
- Proteolytic degradation to constituent amino acids. Short peptide components are rapidly metabolized by serum and tissue peptidases.
- Distribution
- As a polypeptide mixture, components distribute based on molecular weight and tissue affinity. Retinal-derived peptides are hypothesized to show preferential accumulation in retinal tissue based on the bioregulator tissue-specificity model.
- Oral
- Parenteral administration required. Not orally bioavailable due to GI peptidase degradation.
Quick Start
- Typical Dose
- 5mg administered intramuscularly once daily for 10 consecutive days, repeated every 3-6 months for chronic conditions
- Route
- Parabulbar injection, intramuscular injection
Research Protocols
intramuscular Injection
Clinical Research Protocols - Standard protocol: 5 mg Retinalamin reconstituted in 0.5-1 mL sterile water for injection, administered parabulbar (around the eye) or intramuscularly, once daily for 10 days. - Administration routes: Parabulbar injection provides direct local delivery to the periocula
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 5 mg | Daily | 10 days |
| Standard protocol | 5 mg | Once daily | 10 days(Route: Intramuscular Injection) |
Interactions
Peptide Interactions
Epithalon has demonstrated retinal protective effects in retinitis pigmentosa models (PMID: 12195243) and activates telomerase in retinal cells. The combination of systemic Epithalon (telomerase activation, circadian regulation) with local Retinalamin (tissue-specific retinal support) represents a multi-target approach to retinal aging.
Cortagen provides broader neuroprotective effects through CNS gene expression modulation, complementing Retinalamin's retinal specificity. Relevant for patients with combined retinal and neurological age-related decline.
Vilon's thymic bioregulatory activity supports immune function during retinal degeneration, potentially modulating the inflammatory component of diseases like AMD and diabetic retinopathy.
What to Expect
What to Expect
Standard protocol: 5 mg Retinalamin reconstituted in 0.5-1 mL sterile water for injection, administered parabulbar (around the eye) or...
The treatment was associated with stabilization of visual function and slowed disease progression over follow-up periods of 6-12 months.
Continued use as directed
Safety Profile
Common Side Effects
- Generally Well-Tolerated:: Clinical studies report minimal to no adverse effects across hundreds of patients in various trials
- Injection Site Reactions:: As with any injectable medication, potential for local discomfort at intramuscular or parabulbar injection sites
- Long-Term Safety:: Studies spanning up to 2 years show continued safety with regular quarterly administration
- No Systemic Toxicity:: No reports of significant systemic side effects, liver toxicity, or kidney issues in clinical literature
Quality Indicators
What to look for
- Well-established safety profile
- Extensive peer-reviewed research base
Frequently Asked Questions
References (16)
- [1]Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas
→ Retinalamin administered parabulbarly in rabbits exposed to photochemical retinal damage showed functional and morphological retinoprotective effects, with optimal results when treatment began early (day 1) compared to delayed treatment (day 10).
- [5]Objective functional monitoring of retinoprotective treatment in diabetic retinopathy
→ Retinalamin treatment in diabetic retinopathy patients showed significant improvements in pattern electroretinography and flash electroretinography parameters using objective electrophysiological testing with the Diopsys NOVA system.
- [8]Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy
→ A randomized study of 180 patients (355 eyes) showed that intramuscular Retinalamin treatment improved visual acuity and retinal sensitivity in glaucoma patients with normalized intraocular pressure, with effects maintained over 12 months.
- [11]Khavinson VK Peptides and Ageing Neuro Endocrinol Lett (2005)
- [15]
- [2]Neuroprotective therapy in advanced primary open-angle glaucoma
→ Regular use of Retinalamin (5mg intramuscular injections every 3 months) showed positive effects on structural and functional parameters in patients with advanced primary open-angle glaucoma over a 2-year study period.
- [3]Peptide bioregulators: delivery and efficacy
→ Comparison of different administration routes in 498 glaucoma patients showed that intramuscular Retinalamin increased retinal sensitivity by 122 units after 3 months, with improvements maintained at 6 months across all delivery methods tested.
- [4]Effects of peptides on proliferative activity of retinal and pigmented epithelial cells
→ In vitro studies demonstrated that Retinalamin tissue-specifically stimulates proliferation of retinal and pigmented epithelial cells in culture at certain concentrations, showing its direct cellular mechanisms of action.
- [6]Objective structural and functional monitoring of polypeptide retinal neuroprotective therapy in diabetic retinopathy
→ OCT imaging and electrophysiological studies in 56 diabetic retinopathy patients receiving intramuscular Retinalamin showed improvements in ganglion cell complex thickness and functional retinal parameters compared to controls.
- [9]Polypeptide bioregulators in the treatment of different-type abiotrophy of the retina
→ In 33 pediatric patients (ages 4-7) with various types of retinal abiotrophy, Retinalamin treatment stabilized disease progression in all cases, improved visual acuity in 82% of patients, and enhanced electroretinography parameters in 37% over 18 months.
- [10]Evaluation of therapeutic sensitivity of retinal ganglion cells to targeted peptide bioregulator in culture
→ In vitro studies using enriched retinal ganglion cell cultures from mouse retinae demonstrated that Retinalamin shows therapeutic sensitivity and potential for treating glaucomatous optic neuropathy at the cellular level.
- [13]Khavinson V, Razumovsky M, Trofimova S, et al Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa Neuro Endocrinol Lett (2002)
- [16]Khavinson VK, Lezhava TA, Malinin VV Effects of short peptides on lymphocyte chromatin in senile subjects Bull Exp Biol Med (2004)
- [12]Trofimova SV, Khavinson VK, Kozina LS Peptide bioregulators: tissue-specific effects Bull Exp Biol Med (2004)
- [14]Maksimov VY, Trofimova SV, Khavinson VK Retinalamin in the complex treatment of involutional central chorioretinal dystrophy Adv Gerontol (2009)
- [7]Molecular mechanisms of neuroretinoprotection in primary open-angle glaucoma
→ Enzyme immunoassay testing of lacrimal fluid in 23 glaucoma patients showed that 10 intramuscular injections of Retinalamin (5mg daily) significantly modulated brain-derived neurotrophic factor (BDNF) and neuron specific enolase (NSE) levels, indicating neuroprotective molecular mechanisms.
Retatrutide
Retatrutide (LY3437943) is a triple agonist of GIP, GLP-1, and glucagon receptors developed by Eli Lilly for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD). Phase 2 data demonstrated up to 24.2% weight loss at 48 weeks.
Reutericin
Reutericin is a Class II bacteriocin produced by select strains of Lactobacillus reuteri with antimicrobial activity against Gram-positive pathogens. It represents one of several antimicrobial mechanisms employed by L. reuteri, a widely used probiotic species, and is being investigated for microbiome defense and food safety applications.